Since 2023, insurers, reinsurers and other entities have filed numerous federal civil RICO actions alleging coordinated fraud in personal injury and New York Labor Law claims. The complaints generally allege that networks of plaintiffs’ attorneys, runners, recruiters, medical providers and litigation funders coordinated claimant referrals, exaggerated or fabricated accidents and injuries, facilitated excessive or medically unnecessary treatment, and leveraged resulting medical damages to increase settlement values.
These allegations remain disputed and remain to be adjudicated on the underlying merits. Early cases have encountered legal hurdles:
As of October 2026, several significant actions remain active:
Despite the early legal hurdles, the RICO allegations and investigations are impacting personal-injury litigation, bringing “bright light” scrutiny to claimant referral sources, medical treatment patterns and litigation funding:
Although the overall reduction in loss frequency/severity is mostly anecdotal so far, Tradesman Program Mangers has already reported that more than 1,000 cases have been closed without payment, with estimated reserve reductions reportedly approaching $2.3 billion.
Federal RICO remains an unsettled remedy (standing and proximate causation are major obstacles) but insurers continue to file new cases and develop increasingly detailed allegations regarding relationships among law firms, referral sources, medical providers, and litigation funders.
The focus differs by jurisdiction (New York on labor law/personal injury, Florida on auto/PIP, and New Jersey on PIP/medical reimbursement) but the common themes are organized referrals, repetitive provider relationships, treatment escalation, and increased scrutiny of litigation funding.
Insurers are using RICO/state anti-fraud laws to develop a systemic defense, rather than treating suspect claims individually.
To discuss further, please contact our New York Claims team.
This litigation update has been prepared by Transatlantic Reinsurance Company (“TransRe”) for general informational purposes only and does not constitute legal advice. It summarizes publicly available allegations, court decisions and litigation developments as of the publication date. Allegations described in pending litigation have not necessarily been proven, and TransRe takes no position regarding their ultimate merits. All information is provided in good faith, however TransRe makes no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, or completeness of the information provided.
The Best’s Company Report(s) reproduced on this site appear under license from A.M. Best and do not constitute, either expressly or implied, an endorsement of (Licensee)’s products or services. A.M. Best is not responsible for transcription errors made in presenting Best’s Company Reports. Best’s Company Reports are copyright © A.M. Best Company and may not be reproduced or distributed without the express written permission of A.M. Best Company. Visitors to this web site are authorized to print a single copy of the Best’s Company Report(s) displayed here for their own personal use. Any other printing, copying or distribution is strictly prohibited.
Best’s Ratings are under continuous review and subject to change and/or affirmation. To confirm the current rating, please visit the AM Best web site, www.ambest.com.